Erowid Needs Your End-of-the-Year Support
We're an educational non-profit dedicated to providing a balanced
examination of psychoactive drugs and drug use--to reduce harms,
improve benefits, and support appropriate policies. The site is made
possible by $5, $10, and $50 donations from visitors. Please pitch in!

Erowid References Database

Tanner-Smith EE. 
“Pharmacological content of tablets sold as 'ecstasy': results from an online testing service”. 
Drug Alcohol Depend. 2006 Jul 27;83(3):247-54.
PURPOSE: This study examined the pharmacological content of tablets sold as ecstasy, the variation of tablet content by geographic region, and change in tablet content between 1999 and 2005. METHODS: The sample was comprised of tablets anonymously submitted for laboratory testing between 1999 and 2005 (n=1214). Tablet height, width, geographic region, and year of submission were all used to predict the pharmacological content of the tablets.
RESULTS: Overall, 39% of the tablets were comprised of MDMA only, 46% only contained substances other than MDMA and 15% were mixtures of MDMA and other substances. Tablet height and width were inversely related to tablet purity. Ecstasy tablets from California and Florida had decreased likelihoods of containing non-MDMA substances. The purity of tablets decreased over time, which was largely a result of an increasing number of tablets comprised of MDMA along with other substances.
CONCLUSIONS: Ecstasy users may be putting themselves at increased risk of substance-induced anxiety, mood, and psychotic disorders by unknowingly ingesting substances other than MDMA. To decrease detrimental health effects, prevention programs should emphasize the impurity of ecstasy tablets and focus on the health impacts of these substances, particularly for populations at high-risk of substance-induced disorders.
Submit Comment
[ Cite HTML ] Plants & Drugs Mind & Spirit Freedom & Law Arts & Sciences Search About Erowid and Feedback Library & Bookstore Copyrights Memberships noref